Based on ProtTech’s cutting-edge mass spectrometry technique, ProtTech has developed the MHC peptidomics technology platform to De Novo sequence MHC peptide ligands and identify neoantigens without NGS DNA sequencing. This approach is capable of identifying neoantigens from both coding and non-coding regions of the human genome, as well as from the genomes of many human viruses.